September Slump Who?

A bold Nvidia investment that didn’t grab headlines, a paradigm shift for commodity markets, and more.

Sep 20, 2025

Apr 18, 2026

•

1 min read

Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...

Apr 11, 2026

•

2 min read

Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...

Apr 4, 2026

•

2 min read

Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.